Simple Summary MET is a receptor tyrosine kinase encoded by the MET proto-oncogene
that has a significant role in cancer cell progression. Several drugs targeting MET are under …

Leptomeningeal metastases arise from cancer cell entry into the subarachnoid space,
inflicting significant neurologic morbidity and mortality across a wide range of malignancies …

Background Characterization of tumor-related genetic alterations is promising for the
screening of new predictive markers in non-small cell lung cancer (NSCLC). Aim of the study …

Simple Summary Genomic profiling of non-small cell lung cancer (NSCLC) patients offers
the possibility of therapeutic intervention with target-based agents. The analysis of …

PURPOSE MET exon 14 (MET ex14) skipping alterations are oncogenic drivers in non–
small-cell lung cancer (NSCLC). We present a comprehensive overview of MET ex14 …

Introduction MET aberrations, including MET exon 14 skipping mutation and amplification,
are present in~ 5% of non-small cell lung cancer (NSCLC) cases, and these levels are …

Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted
of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a …

The treatment of non-small cell lung cancer (NSCLC) has recently evolved with the
introduction of targeted therapy based on the use of tyrosine kinase inhibitors (TKIs) in …

Simple Summary Liquid biopsy has recently been introduced as a novel method in cancer
diagnostics. It is less invasive for patients than conventional tissue biopsies, as the assay …

The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC),
largely owing to the improved control of systemic disease provided by immune-checkpoint …